TITLE

The Role of Aspirin in the Prevention of Thrombotic Complications of Thalidomide and Anthracycline-Based Chemotherapy for Multiple Myeloma

AUTHOR(S)
Baz, Rachid; Liang Li; Kottke-Marchant, Kandice; Srkalovic, Gordan; McGowan, Bridget; Yiannaki, Erin; Karam, Mary Ann; Faiman, Beth; Jawde, Rony Abou; Andresen, Steven; Zeldis, Jerome; Hussein, Mohamad A.
PUB. DATE
December 2005
SOURCE
Mayo Clinic Proceedings;Dec2005, Vol. 80 Issue 12, p1568
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To study the efficacy of daily low-dose aspirin (81 mg orally) In decreasing the incidence of venous thromboembolic events (VTEs) in patients with multiple myeloma receiving pegylated doxorubicin, vincristine, and decreased-frequency dexamethasone, plus thalidomide (DVd-T). PATIENTS AND METHODS: In this phase 2 clinical trial of DVd-T, conducted by the Cleveland Clinic Foundation from August 2001 to October 2003,105 patients were enrolled. The first 35 patients experienced increased numbers of VTEs, von Willebrand levels and platelet aggregation to ristocetin before and after treatment with DVd-T increased significantly, suggesting a pathophysiology involving platelet-endothelial interaction. Aspirin was added to the regimen, thus generating 3 patient groups: group 1 received aspirin from the start of DVd-T treatment before the study began (58 patients), group 2 received aspirin after the start of DVd-T treatment and after the study began (26 patients), and group 3 did not receive daily low-dose aspirin during the study (19 patients). Two patients being treated with warfarin for other indications were excluded from the study. The primary end point for this study was the incidence of VTE in the form of either deep venous thrombosis or pulmonary embolism. Secondary end points were the time to the first VTE, time to the composite end point of death or first VTE, and incidence of bleeding complications. RESULTS: After a median follow-up of 24 months, on an intent-to-treat basis, 26 posttreatment VTEs occurred after a median of 90 days, with 19% occurring in group 1,15% in group 2, and 58% in group 3. Following multivariate time-to-event analysis, aspirin use continued to be associated with lower relative risk of VTE (hazard ratio, 0.22; confidence interval, 0.10-0.47; P<.001) and of the composite end point (hazard ratio, 0.28; confidence interval, 0.15- 0.51; P<.001). CONCLUSION: Daily low-dose aspirin (81 mg orally) given to patients with newly diagnosed and relapsed/refractory multiple myeloma who were receiving DVd-T reduced the incidence of VTEs without an increase in bleeding complications.
ACCESSION #
19168649

 

Related Articles

  • Thalidomide.  // Reactions Weekly;3/15/2008, Issue 1193, p27 

    The article presents case reports of nine patients who developed arterial and venous thrombotic complications after receiving thalidomide for multiple myeloma. The patient characteristics are described including their sex, age, thrombosis onset and lesion type. All of them received oral...

  • Thalidomide.  // Reactions Weekly;5/24/2008, Issue 1203, p38 

    The article describes two cases of adverse reaction to thalidomide. Two male patients diagnosed with multiple myeloma experienced arterial thrombi during treatment with thalidomide. After surgery both patients received enoxaparin sodium and started treatment with warfarin and aspirin. During the...

  • Emerging Treatment Options in the Management of Multiple Myeloma. Schlossman, Robert L. // Journal of Managed Care Medicine;2013, Vol. 16 Issue 1, p25 

    The article focuses on the concept of managing multiple myeloma with the onset of novel agents such as thalidomide, lenalidomide, and bortezomib. Since MM is not a curable disease yet, the researchers are combining these agents with or without the older agents to come up with an effective...

  • Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Hovenga, Sjoerd; Daenen, Simon M. G. J.; de Wolf, Joost T. M.; van Imhoff, Gustaaf W.; Kluin-Nelemans, Hanneke C.; Sluiter, Wim J.; Vellenga, Edo // Annals of Hematology;May2005, Vol. 84 Issue 5, p311 

    Thalidomide is an effective agent for patients with refractory multiple myeloma (MM) with a response rate of 30-40% at doses of 200-800 mg but with considerable side effects. We questioned whether lower doses of thalidomide in combination with a daily dose of cyclophosphamide might be an...

  • Thalidomide.  // Reactions Weekly;7/5/2008, Issue 1209, p30 

    The article describes the case of a 72-year-old man receiving thalidomide for multiple myeloma who developed pulmonary embolism. The patient had been receiving thalidomide 200 milligram (mg)/day, melphalan and dexamethasone for approximately 4 months before being admitted with dyspnoea and a dry...

  • Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma. Stöhr, Elisabeth; Schmeel, Frederic; Schmeel, Leonard; Hänel, Mathias; Schmidt-Wolf, Ingo // Journal of Cancer Research & Clinical Oncology;Dec2015, Vol. 141 Issue 12, p2205 

    Purpose: Treatment options for patients with relapsed and refractory multiple myeloma have improved since the introduction of immune-modulating agents such as lenalidomide and thalidomide. However, almost all patients relapse and suffer from an increasing amount of adverse events due to multiple...

  • Thalidomide.  // Reactions Weekly;3/14/2009, Issue 1243, p42 

    The article presents two case studies of women with multiple myeloma who developed hepatotoxicity while receiving thalidomide. The first patient started receiving 28-day cycles of thalidomide 50 mg/day and pulse dexamethasone with weekly thalidomide dosage increases of 50 mg/day to a maximum of...

  • Thalidomide.  // Reactions Weekly;4/11/2009, Issue 1247/1248, p33 

    The article describes the case of a 71-year-old man who developed pneumonitis following the administration of thalidomide for multiple myeloma. The patient became febrile 12 days after receiving thalidomide. Thalidomide and other antibacterial therapy were stopped and the patient's symptoms...

  • WPŁYW TALIDOMIDU NA AKTYWACJĘ PŁYTEK KRWI I UKŁAD KRZEPNIĘCIA U CHORYCH NA SZPICZAKA MNOGIEGO. ROBAK, MARTA; TRELIŃSKI, JACEK; CHOJNOWSKI, KRZYSZTOF // Problemy Terapii Monitorowanej;sep2010, Vol. 21 Issue 3, p165 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics